Single-use Precision Filter Infusion Set
Conditions
Brief summary
This study is a pre-market clinical trial of a single-use precision filter infusion set for pumps, to evaluate the safety and effectiveness of a single-use precision filter infusion set for pumps after being used in humans, and to provide clinical evidence for the official application of the product in China
Detailed description
This experiment compares the single-use precision filter infusion set produced by Shandong Xinhua Ande Medical Products Co., Ltd. for the same intended use that has been approved to market, and compares the performance of the two products in clinical use, the overall pass rate, and the occurrence of phlebitis Rates and adverse events are used to evaluate the safety and effectiveness of single-use precision filtration infusion sets for pumps.
Interventions
DEVICEsingle-use precision filtered infusion sets
single-use precision filter infusion set (Dalian JMS Medical Apparatus Co., Ltd.)
DEVICEsingle-use precision filter infusion set with needle
single-use precision filter infusion set with needle (Shandong Zhongbao Kang Medical Apparatus Co., Ltd.)
Sponsors
Beijing Friendship Hospital
Peking University Third Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. age 18 years or older, gender not limited; 2. intravenous infusion requiring drug filtration, flow regulation, dosing and extension of infusion line; 3. not participating in other clinical trials within one month; 4. able to understand the purpose of the trial, voluntarily participate and sign the informed consent; 5. willing to follow up and evaluate according to the requirements of the trial protocol.
Exclusion criteria
1. Patients with positive pregnancy test in women of childbearing age or lactating women; 2. Patients with uncontrollable cardiomyopathy, heart failure and unable to tolerate infusion; 3. Patients with uncontrollable decompensated renal function, especially in the anuric phase of acute renal failure and unable to tolerate infusion; 4. Patients with uncontrollable extensive inflammation of the lung parenchyma, pulmonary congestion, pulmonary edema and unable to tolerate infusion; 5. 0.2um size Test devices combined with any of the following drugs or preparations: fatty milk type, blood products type (blood cells, globulin, etc.), drugs that will produce insoluble precipitates with each other, etc.; 6, patients who are clinically infused with very small amounts of drugs (due to residual test line may reduce the amount of drugs delivered to patients); 7, puncture sites with inflammation, tumors, trauma, scars, etc.; 8, those who may be allergic to product materials; 9 Patients with AIDS; 10\. Patients with mental disorders; 11. Other patients who are considered by the investigator to be unsuitable for participation in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vital signs | 2 hr after injection | changes in breathing, resting heart rate, blood pressure, body temperature, etc |
| adverse events and complications | 2 hr after injection | The incidence of adverse events and complications |
| number of heat source reactions | 2 hr after injection | Heat source reactions caused by the application of extension tubes, such as nausea, vomiting, chills, fever, etc., are key safety indicators |
Countries
China
Outcome results
None listed